Skip to main content
. 2021 Jun 25;9(7):700. doi: 10.3390/vaccines9070700

Figure 1.

Figure 1

Anti-spike (S)- and anti-receptor-binding domain (RBD) specific immunglobuline G (IgG) response ≥ 21 days after infection with SARS-CoV-2 variants of concern (VOCs: B.1.1.7, filled green dots or diamonds; B.1.351, empty green dots or diamonds) or after first (1) and second vaccination (2) with messenger ribonucleic acid (BNT162b2, grey dots or diamonds; mRNA-1273, red dots or diamonds) and vector (AZD1222, blue dots or diamonds) vaccines. The mean titer and the 95% confidence intervals are given per each study group. All titers were measured in Binding Antibody Units per milliliter (BAU/mL). The prevalence of anti-S/anti-RBD IgG is indicated by a black dot or diamond. The cut-off values for seropositivity (in BAU/mL) of the anti-S and anti-RBD IgG assays are indicated by dotted lines.